{"id":"dfpp-peg-ifn-rbv","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Vascular access complications (from DFPP)"},{"rate":null,"effect":"Depression/mood changes"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Double filtration plasmapheresis (DFPP) is an extracorporeal blood purification technique that selectively removes large molecular weight substances including immune complexes and immunoglobulins. When combined with pegylated interferon-alpha (Peg-IFN), which activates innate immunity and has direct antiviral effects, and ribavirin (RBV), a nucleoside analog that inhibits viral RNA synthesis, this triple modality targets hepatitis C virus through multiple mechanisms: reducing viral load, clearing immune-mediated damage, and enhancing interferon-based antiviral immunity.","oneSentence":"DFPP removes circulating immune complexes and pathogenic antibodies, while pegylated interferon-alpha and ribavirin work synergistically to inhibit hepatitis C virus replication and enhance immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:44.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection, particularly in treatment-experienced or difficult-to-treat patients"}]},"trialDetails":[{"nctId":"NCT00977054","phase":"PHASE4","title":"Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2009-09","conditions":"Hepatitis C","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DFPP: Plasmaflo + Cascadeflo EC-50W (Asahi)","Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche)","RBV: Copegus (Hoffman La-Roche)"],"phase":"marketed","status":"active","brandName":"DFPP + Peg-IFN + RBV","genericName":"DFPP + Peg-IFN + RBV","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DFPP removes circulating immune complexes and pathogenic antibodies, while pegylated interferon-alpha and ribavirin work synergistically to inhibit hepatitis C virus replication and enhance immune response. Used for Chronic hepatitis C virus infection, particularly in treatment-experienced or difficult-to-treat patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}